Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 12 (December)

1. Sensitive Detection of KIT D816V in Patients with Mastocytosis.
   Clin Chem, 52(12): 2250-7. [Abstract] [Full-text]
2. Platelet-derived growth factor receptor-beta in Gorham's disease.
   Nat Clin Pract Oncol, 3(12): 693-7. [Abstract] [Full-text]
3. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
   Cancer Res, 66(23): 11314-22. [Abstract] [Full-text]
4. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
   Clin Cancer Res, 12(23): 7180-6. [Abstract] [Full-text]
5. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
   Clin Cancer Res, 12(23): 6920-8. [Abstract] [Full-text]
6. Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS.
   Am J Clin Pathol, 127(1): 89-96. [Abstract] [Full-text]
7. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
   Hematol Oncol, 24(4): 196-204. [Abstract] [Full-text]
8. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
   Oncogene, 25(58): 7618-34. [Abstract] [Full-text]
9. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
   N Engl J Med, 355(23): 2408-17. [Abstract] [Full-text]
10. Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era.
    Ann Surg Oncol, 13(12): 1596-603. [Abstract] [Full-text]
11. Clinical Outcome in Gastrointestinal Stromal Tumor Patients who Interrupted Imatinib after Achieving Stable Disease or Better Response.
    Jpn J Clin Oncol, 36(11): 704-11. [Abstract] [Full-text]
12. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
    Exp Hematol, 34(12): 1709-19. [Abstract] [Full-text]
13. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Adv Cancer Res, 96: 213-68. [Abstract] [Full-text]
14. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.
    Acta Crystallogr D Biol Crystallogr, 63: 80-93. [Abstract] [Full-text]
15. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
    Histopathology, 49(6): 576-81. [Abstract] [Full-text]
16. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.
    Leukemia, 21(1): 93-101. [Abstract] [Full-text]
17. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
    Ann Surg Oncol, 14(1): 134-42. [Abstract] [Full-text]
18. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Ann Surg Oncol, 14(1): 14-24. [Abstract] [Full-text]
19. Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment.
    Acta Haematol, 117(4): 191-196. [Abstract] [Full-text]
20. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors.
    Cancer, 107(12): 2833-41. [Abstract] [Full-text]
21. Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation.
    Transplant Proc, 38(10): 3231-2. [Abstract] [Full-text]
22. Druggable signaling proteins.
    Methods Mol Biol, 361: 1-24. [Abstract] [Full-text]
23. Combined-modality strategy for gastrointestinal stromal tumors.
    Semin Oncol, 33: 75-8. [Abstract] [Full-text]
24. Successful gastrointestinal cancer drug development.
    Semin Oncol, 33: 24-7. [Abstract] [Full-text]
25. cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib.
    Cancer Chemother Pharmacol, 59(3): 349-60. [Abstract] [Full-text]
26. Gardner's syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy.
    World J Surg Oncol, 4: 96. [Abstract] [Full-text]
27. c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase.
    Mol Pharmacol, 71(1): 61-72. [Abstract] [Full-text]
28. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Clin Cancer Res, 12(24): 7374-9. [Abstract] [Full-text]
29. Usefulness of Quantitative Assessment of JunB Gene Expression as a Marker for Monitoring Chronic Myeloid Leukemia Patients Undergoing Imatinib Therapy.
    Int J Hematol, 84(5): 425-31. [Abstract] [Full-text]
30. Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity.
    Gastroenterology, 131(6): 1734-42. [Abstract] [Full-text]
31. Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form.
    J Pharm Biomed Anal, 43(2): 722-6. [Abstract] [Full-text]
32. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Blood, 109(1): 315-22. [Abstract] [Full-text]
33. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
    Blood, 109(1): 58-60. [Abstract] [Full-text]
34. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
    Blood, 109(1): 61-4. [Abstract] [Full-text]
35. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Blood, 109(1): 306-14. [Abstract] [Full-text]
36. Kit signaling is essential for development and maintenance of interstitial cells of Cajal and electrical rhythmicity in the embryonic gastrointestinal tract.
    Dev Dyn, 236(1): 60-72. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.